Imcyse
PrivateLast Round
Series B
Extension
Feb 17, 2021
Total Funding Raised
$66.18M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Imcyse operates in Healthcare & Life Sciences and is based in Liège. Its latest recorded funding round was a Series B Extension round in February 2021.
Imcyse is a biotechnology company that develops active specific immunotherapies for the treatment and prevention of severe chronic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Imcyse Comparables
Compare Imcyse with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Anokion | 88% | |
| COUR Pharmaceuticals | 86% | |
| Phaim Pharma | 85% |
For institutional investors. Book with your work email.
Imcyse Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Feb 17, 2021 | ||||
| Grant | Jul 28, 2020 | ||||
| Debt | Jun 18, 2019 | ||||
| Grant | Jun 18, 2019 | ||||
| Series B | Jun 18, 2019 | ||||
Grant | Jun 6, 2017 |
For institutional investors. Book with your work email.
Imcyse Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Federal Holding and Investment Company | Series B Extension, Series B |
| EQT Life Sciences | Series B Extension, Series B |
| Noshaq | Series B Extension, Series B |
| Epimede | Series B Extension, Series B |
| Société Régionale d'Investissement de Wallonie | Series B Extension, Series B |
| KU Leuven | Series B Extension, Series B |
| Pfizer | Series B Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 31% MoM.
- Feb 17, 2021
$26M round led by Pfizer
For institutional investors. Book with your work email.
Imcyse Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Imcyse's valuation, stock price, and market status.
Is Imcyse a public or private company?
Imcyse is a private company.
What is the current stock price of Imcyse?
Imcyse is a private company, so its shares have no public market price. Caplight tracks Imcyse's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Imcyse worth (valuation)?
Valuation information for Imcyse is not publicly available.
Can I buy Imcyse stock?
Imcyse shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Imcyse's last funding round?
Imcyse's most recent funding round was Series B Extension on February 17, 2021.
Who are the main investors in Imcyse?
Key investors in Imcyse include EQT Life Sciences, Pfizer.
Will Imcyse IPO soon?
No public IPO plans have been announced for Imcyse.
How can I track Imcyse secondary market activity?
Caplight tracks bids, offers, and trades in Imcyse's shares on secondary markets.